Beijing GoBroad Hospital
北京高博医院
Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Beijing GoBroad Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌0 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌0 papers led1 open trial led
- Multiple myeloma多发性骨髓瘤0 papers led2 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led4 open trials led
- IgG4-related diseaseIgG4相关性疾病0 papers led1 open trial led
- Myasthenia gravis重症肌无力0 papers led1 open trial led
Not listed for: Nasopharyngeal carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07688291
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingQL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07049185
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status2
Cancer
Hepatocellular carcinoma
肝细胞癌17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07242417
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingPhase I Study of OriC902 in Treatment of Advanced HCC
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06891742
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of DEG6498 in Participants With Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07244835
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status3
Blood disorders
Multiple myeloma
多发性骨髓瘤15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003555
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingDual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07003568
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06182696
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status3
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT06326008
Age 1 year to 18 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingClinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06890494
Age 18 years to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingClinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06343090
Age 1 year to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingCIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06389305
Age 1 year to 39 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status4
- Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
- Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
- Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
- CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Other diseases
IgG4-related disease
IgG4相关性疾病11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07593911
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Myasthenia gravis
重症肌无力11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07593911
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
北京高博医院
Beijing GoBroad Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.